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In 2001, a previously well 21 year-old nulliparous female presented
to her General Practitioner with a 6 week history of lower abdominal
pain, occasional diarrhoea and gastro-oesophageal reﬂux. For several
days prior she had also noted dyspnoea on exertion. There was no
weight loss or nausea. Her menstrual cycles had been unremarkable
besides ‘heavier’ bleeding during her LMP. She had undergone an elec-
tive TOP 22 months prior and had had a normal pelvic ultrasound at
that time. She had no signiﬁcant medical history and no family history
of ovarian or breast cancer. She used no medications, never smoked
and occasionally consumed modest alcohol.
Her BMI was 23 kg/m2. Physical examination revealed a distended
abdomen and a large pelvic mass inseparable from the uterus with
abnormal tissue mass palpable in the rectovaginal pouch. Pelvic ultra-
sound conﬁrmed a large 13.7×8 cm mass with solid and cystic areas
suspicious for ovarian carcinoma. Laboratory evaluation showed:
β-hCG: b2 IU/L; CEA: 0.1 μg/L; CA125: 849 U/mL; AFP: b5 μg/L;
LDH: 698 IU/L. Liver, renal, thyroid, coagulation proﬁle and blood
count tests were normal besides Hb 114 g/L. Serum calcium was
not measured. Abdominal and pelvic CT scan revealed a large pelvic
mass (128×109 mm) with a heterogeneous internal structure of
contrast-enhancing solid and multiloculated components. Ascites⁎ Corresponding author at: Auckland City Hospital, Park Rd, Grafton, Auckland,
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Open access under CC BY-NC-ND license .was noted. Para-aortic lymphadenopathy was present with the largest
node measuring 40×20 mm below the left renal vein, displacing the
left gonadal vessels laterally. A small hypodense area in the left lobe of
liver, mild splenomegaly (126 mm) and a 10 mm simple cyst in L
pole of L kidney were seen.
There was no evidence of omental caking, peritoneal nodules or
pelvic lymphadenopathy. A chest X-ray was clear.
One month after initial presentation, the patient underwent explor-
atory and debulking laparotomy by an experienced gynaecologic
oncology subspecialist. Three litres of ascites was drained and the
tumour involving the left ovary was resected along with the left
fallopian tube. Small nodules in the uterovesical fold and hepatorenal
angle, and enlarged left para-aortic nodes were resected. Omentectomy
was performed as well as multiple peritoneal and diaphragmatic
biopsies. A biopsy was taken from a cyst in the right ovary. The intra-
operative frozen-section histological diagnosis was dysgerminoma.
There remained a 0.5 cm thick carpet of tumour in the
pouch-of-Douglas which would have required en-bloc total abdominal
hysterectomy and abdomino-perineal resection; therefore it was not
resected on the basis of the intraoperative histological diagnosis. A small
right pleural effusion had developed on a preoperative chest X-ray,
which enlarged post-operatively but resolved without intervention. The
post-operative course was otherwise complicated by a requirement for
transfusion of 3 units of packed red cells and an E. coli urinary tract in-
fection. Post-operative serum calcium was normal at 2.5 mmol/L.
The formal diagnosis of the 1052 g (180×130×110 mm) ovarian
mass performed by the hospital pathology department was ‘small
cell carcinoma of the ovary NOS’. There was no omental disease and
the right ovarian cyst was a corpus luteum. Otherwise the disease was
present in the peritonealwashings and all surgical specimens submitted
as above. The FIGO stage was 3C. Immunocytochemistry was reactive
for cytokeratin and vimentin but nonreactive for all of the following: al-
kaline phosphatase, CD31, CD34, CD30, CD 45, CD20, and CD3. Samples
were sent to a specialist gynaecological pathologist (PR) for review and
the diagnosis of small cell carcinomaof ovary, hypercalcaemic type,was
conﬁrmed. A uniform proliferation of small to medium sized cells with
pleiomorphic nuclei and variable, focally vacuolated amphophilic cyto-
plasmwas described. Predominately solid growth pattern with nests of
cells and follicle-like spaces with relatively little necrosis and capsular
invasion was seen. Epithelial, trophoblastic or teratomatous elements
were not found. Normal primary and primordial ovarian follicles
scattered at the tumour periphery ruled out a dysgenetic gonad.
Table 1
Characteristics of long-term survivors of advanced stage small cell carcinoma of the ovary.






Serum calcium Surgery Adjuvant Outcome
Young et al. (1994) III 16 NR NR NR HT BSO Radio-therapy Recurrence 5 years,
died 5.5 years
Young et al. (1994) III 21 NR NR NR USO+debulking MAC A+W+D 2 years
Young et al. (1994) III 19 NR NR NR HT BSO MAC A+W 2 years
Tewari et al. (1997) IIIC 26 12 Normal Normal HT BSO+debulking VPCBAE A+W 5.5 years
Powell et al. (1998) IIIC 21 12 28.1 Normal USO+omentectomy+debulking VPCBAE A+W 2 years
Rana et al. (2004) IIIC 19 15 173 Normal USO+OMENTECTOMY+biopsies VPCBAE A+W 2.5 years
Distelmaier et al. (2006) IIIC 16 27 NR Normal USO+biopsies MAC A+W 2.5 years
Kanwar et al. (2008)a IIIC 17 18 Normal Normal USO VPBCAE A+W 3 years
Christin et al. (2008) IIIC 12 10 133 NR Primary and interval radical debulking PCEA+carboplatin A+W 14 years
Dykgraaf et al. (2009) IIIC 23 11 45 Normal USO+interval lyphaden-ectomy BEP A+W 5.8 years
NR: not reported; HT: Hysterectomy; BSO/USO: Bilateral/Unilateral salpingo-oophorectomy; MAC: multiagent chemotherapy (details not available); VPCBAE: vinblastine, cisplatin,
cyclophosphamide, bleomycin, doxorubicin, etoposide; BEP: bleomycin, etoposide, cisplatin; A: alive; W: well; D: disease.
a Staging based on PET scan-positive nodes instead of surgical staging.
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5% of individual cells and mild patchy staining with epithelial mem-
brane antigen (EMA). Neuron speciﬁc enolase (NSE) showed moderate
diffuse positivity. Alpha-inhibin, AFP, β-hCG, PLAP negative.
Ongoing input from a medical oncologist was arranged. Chemo-
therapy was commenced 22 days after surgery allowing for recovery
and conﬁrmation of the ﬁnal pathological assessment. Serum Ca 125
had reduced from 849 to 161 IU prior to chemotherapy. Chemotherapy
cycles consisted of 3 sequential days of dual therapy with vinlastine/
cisplatin, bleomycin/cyclophosphamide, and doxorubicin/etoposide
respectively, ﬁrst described by Senekjian et al. (1989) and subse-
quently used successfully by Tewari et al. (1997). Serum CA125
normalised after 2 cycles. Complications included neutropaenia and
severe thrombocytopaenia. Owing to these and the fact that both the
CA125 had normalised and there was no CT evidence of disease, she
completed 4 out of 6 planned cycles.
Regular follow-up thereafter has shown no clinical or radiological
progression of disease and stable normal serum CA125 measurements.
Menstrual cycles resumed normally and in 2009 she had a full term
pregnancy and delivery of a healthy infant.Discussion
This favourable outcome in this aggressive disease is an exception
to the rule. The positive prognostic features of SCCO are described by
Young et al., studying 150 cases of SCCO: Age>30 years, normal-range
serumcalcium, tumour size of b10 cmand early stage disease; variables
that are in contrast to this case. In that same study the follow-up data
on 52 patients with stage III disease reported just one survivor (2%) at
2.5 years. Further review of the literature reports of cases of advanced
stage SCCO with longer term (>2 years) survival yields the following
individualised data: [Table 1].
It is noted that in the cases of Dykgraaf and Distelmaier the initial
histological impressions were dysgerminoma and teratoma respective-
ly, which similarly to our case resulted in incomplete primary surgical
staging and debulking, fortuitously preserving fecundity. Resection bi-
opsy of retroperitoneal lymph nodes staged advanced disease in our
case. The cases from Powell, Dykgraaf and Rana report resumption of
menstruation following treatment, this detail is not reported in the
remaining studies. In our case post‐operative serum calcium was nor-
mal, similarly hypercalcaemia (where recorded) is absent in 6 cases
in the above series of successfully treated patients with advanced dis-
ease. This may be an important prognostic factor in agreement with
Young et al. The use of VPCBAE multiagent chemotherapy in our case
was based upon the successes observed by Senekjian and Tewari andhas doubtless contributed to this success also, due to the residual dis-
ease observed at laparotomy. As in our case, the use of imaging and tu-
mour markers has been reported to be useful in excluding recurrence
during follow-up (Rana et al., 2004).
This case is notable not only for the successful reproductive out-
come, but also as the second-longest reported survivor of advanced
stage III disease now more than 10 years from diagnosis at the time
of writing, compared to a 14 year survivor reported in 2008 (Christin
et al., 2008).
Conclusion
SCCO is a rare and very aggressive cancer that affects young
women. Fewer than 200 cases have been reported in the liter-
ature and thus standardized management is yet to be determined.
Women with this condition should be offered multi-agent platinum
based chemotherapy. In light of this case report, and others in the
literature, advice on surgical management is problematic. Hysterecto-
my, bilateral salpingo-oophorectomy and surgical debulking would
normally be standard management, though perhaps in some circum-
stances, following careful discussion, fertility sparing surgery can be
considered.
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